Revenue YoY
—
Operating Income YoY
+178.54%
Net Income YoY
-17.60%
Net Margin Δ
—
Net income bridge for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: −$11.12M-17.60%
Profit bridge breakdown for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$63.18M | — |
| Revenue | $0.00 | 0.0% |
| Cost of Revenue | −$114.00K | -1.0% |
| Operating Expenses | $124.92M | +1123.0% |
| Other Income / Expense | −$135.93M | -1222.0% |
| Income Tax | $0.00 | 0.0% |
| Net Loss | −$74.31M | — |
- Prior Net Income−$63.18M
- Revenue$0.00
- Cost of Revenue−$114.00K
- Operating Expenses$124.92M
- Other Income / Expense−$135.93M
- Income Tax$0.00
- Net Loss−$74.31M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement